Summary
We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and welltolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
1992;352–357
Tseng A Jr, Coleman C N, Cox R Set al. The treatment of malignant histiocytosis. Blood, 1984; 64: 48
Zucker J M, Caillaux J M, Vanel Det al. Malignant histiocytosis in childhood: Clinical study and therapeutic results in 22 cases. Cancer, 1980, 45: 2821
VP16, 1989, 12, 8
Vogelzang N J, Raghavan D, Kennedy B J. VP-16-213 (etopiside): The mandrake root from Essyk-Kul. Am J Med, 1982; 72: 136
Rowe J M, Chang A Y C, Bennett J M. Aclacinomycin A and etoposide CVP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood, 1988, 71: 992
Seljelid R, Eskeland T. The biology of macrophages: In general principles and properties. Eur J Haematol, 1993, 51: 267
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feng-ru, L., Er-gu, Y. Etoposide-based combination chemotherapy in malignant histiocytosis. Journal of Tongji Medical University 14, 227–229 (1994). https://doi.org/10.1007/BF02897674
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02897674